Drug intelligence / Profile preview

LIV-001

Development stage: Unknown
Lead developer: Liviom
Modality: Small Molecules
Administration: Ophthalmic

Overview

LIV-001 (Livionex Band Keratopathy Eye Drops) is a topical ophthalmic solution currently in Phase 3 clinical development for the treatment of band keratopathy. Band keratopathy is a corneal disease characterized by the progressive accumulation of calcium deposits in the Bowman's layer, which can lead to significant vision loss, ocular irritation, and pain. LIV-001 utilizes a proprietary "activated" EDTA (ethylenediaminetetraacetic acid) technology designed to enhance the penetration and chelation of these calcific deposits. The goal of the therapy is to provide a non-invasive, pharmacological alternative to the current standard of care, which typically involves surgical debridement of the corneal epithelium followed by manual chelation with EDTA.

Other names: Livionex Band Keratopathy Eye DropsActivated EDTA Eye Drops

Beyond the preview

Go deeper on LIV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIV-001.

Explore the full profile